Related Experiment Video
Updated: Mar 9, 2026
One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
Published on: June 25, 2010
Testing for homocysteine in clinical practice
11 South West Thames Faculty, Royal College of General Practitioners, London, UK; Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
Insights
High homocysteine levels, a risk factor for cardiovascular disease, may be treatable. Lowering homocysteine shows promise in preventing cognitive decline and brain shrinkage in early Alzheimer's disease.
Area of Science:
- Cardiovascular disease research
- Neurology
- Metabolic disorders
Background:
- Elevated blood homocysteine was initially overlooked as a significant factor in cardiovascular disease (CVD) development.
- Previous trials on lowering homocysteine in advanced disease yielded limited benefits, particularly for patients on anti-platelet drugs.
Purpose of the Study:
- To evaluate the role of homocysteine in cardiovascular health and neurological conditions.
- To assess the efficacy of homocysteine-lowering strategies in early disease stages and as a preventive measure.
- To highlight the potential of homocysteine testing in clinical practice.
Main Methods:
- Review of existing clinical trial data on homocysteine-lowering treatments.
- Analysis of recent evidence linking homocysteine levels to cognitive decline and Alzheimer's disease.
- Assessment of the diagnostic and therapeutic implications for general practitioners.
Main Results:
- While treatments failed in moderately advanced disease, evidence suggests benefits in very early disease stages and prevention.
- Lowering high homocysteine significantly reduces cognitive decline and brain atrophy linked to Alzheimer's disease.
- The study advocates for more frequent homocysteine testing in both National Health Service (NHS) and private practices.
Conclusions:
- Homocysteine management is crucial for cardiovascular health and neuroprotection.
- Early detection and intervention targeting homocysteine levels can mitigate Alzheimer's progression.
- Increased utilization of homocysteine testing by healthcare providers is recommended.
Abstract:
The theory that raised blood homocysteine is a major factor in the development of cardiovascular disease was initially rejected by the medical establishment. Trials of a treatment to lower homocysteine in moderately advanced disease have failed to show benefits (except in those not treated with anti-platelet drug), but there is mounting evidence for a role in treatment of very early disease and as a preventive strategy. Recent evidence has shown that lowering of high blood homocysteine significantly slows cognitive decline and the brain shrinkage associated with Alzheimer's disease. This is a test that should be done more frequently by National Health Service (NHS) general practitioners and private practitioners.
More Related Videos
08:41Integration of Miniaturized Solid Phase Extraction and LC-MS/MS Detection of 3-Nitrotyrosine in Human Urine for Clinical Applications
Published on: July 14, 2017
07:24A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Serum Laboratory Studies, Stool Test, Breath Test
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests